title: Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
abstract: BACKGROUND
  No direct proof has been brought to light in a link between hypoxic changes in glioma models and the effects of antiangiogenic treatments. Here, we assessed the sensitivity of the detection of hypoxia through the use of (18)F-fluoromisonidazole positron emission tomography ([(18)F]-FMISO PET) in response to the evolution of the tumor and its vasculature.
  
  
  METHODS
  Orthotopic glioma tumors were induced in rats after implantation of C6 or 9L cells. Sunitinib was administered from day (D) 17 to D24. At D17 and D24, multiparametric magnetic resonance imaging was performed to characterize tumor growth and vasculature. Hypoxia was assessed by [(18)F]-FMISO PET.
  
  
  RESULTS
  We showed that brain hypoxic volumes are related to glioma volume and its vasculature and that an antiangiogenic treatment, leading to an increase in cerebral blood volume and a decrease in vessel permeability, is accompanied by a decrease in the degree of hypoxia.
  
  
  CONCLUSIONS
  We propose that [(18)F]-FMISO PET and multiparametric magnetic resonance imaging are pertinent complementary tools in the evaluation of the effects of an antiangiogenic treatment in glioma.
authors.affiliation: CERVOxy group, UMR 6232 CI-NAPS. CNRS, Université de Caen Basse-Normandie, Université Paris-Descartes, CEA. GIP CYCERON, Bd Henri Becquerel, BP5229, 14074 CAEN cedex, France. valable@cyceron.fr
authors.forename: Samuel
authors.initials: S
authors.lastname: Valable
authors.forename: Edwige
authors.initials: E
authors.lastname: Petit
authors.forename: Simon
authors.initials: S
authors.lastname: Roussel
authors.forename: Léna
authors.initials: L
authors.lastname: Marteau
authors.forename: Jérôme
authors.initials: J
authors.lastname: Toutain
authors.forename: Didier
authors.initials: D
authors.lastname: Divoux
authors.forename: Franck
authors.initials: F
authors.lastname: Sobrio
authors.forename: Jérôme
authors.initials: J
authors.lastname: Delamare
authors.forename: Louisa
authors.initials: L
authors.lastname: Barré
authors.forename: Myriam
authors.initials: M
authors.lastname: Bernaudin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001692:Biological Transport; D001921:Brain / Q000098:blood supply / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D001932:Brain Neoplasms / Q000098:blood supply / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D015687:Cell Hypoxia / Q000187:drug effects; D045744:Cell Line, Tumor; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004195:Disease Models, Animal; D005910:Glioma / Q000098:blood supply / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D007700:Kinetics; D008279:Magnetic Resonance Imaging; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010539:Permeability / Q000187:drug effects; D049268:Positron-Emission Tomography; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; C031843:fluoromisonidazole; D008920:Misonidazole; D000077210:Sunitinib